Factors that limit the effectiveness of herpes simplex virus type 1 for treatment of oral cancer in mice

Clinical Cancer Research

Volumn 11, Issue 8, 2005, Pages 3109-3116

  Shillitoe, Edward J ^a   Pellenz, Christopher ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; ONCOLYTIC VIRUS; PROBIOTIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CELL CYCLE S PHASE; CELL DIVISION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; EXPLANT; FEMALE; HERPES SIMPLEX VIRUS 1; IMMUNE DEFICIENCY; IMMUNE SYSTEM; MOUSE; MOUSE STRAIN; MOUTH CANCER; NATURAL KILLER CELL; NONHUMAN; PHAGOCYTE; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; TUMOR CELL; VIRUS REPLICATION;

ANIMALS; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; HERPESVIRUS 1, HUMAN; IMMUNITY, CELLULAR; IMMUNITY, NATURAL; MICE; MICE, INBRED C3H; MICE, INBRED NOD; MICE, NUDE; MICE, SCID; MOUTH NEOPLASMS; SPECIES SPECIFICITY; VERO CELLS; VIRUS REPLICATION;

EID: 17144414128     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2302     Document Type: Article

References (23)

1. Lou E, Kellman R, Hutchison R, Shillitoe E. Clinical and pathological features of the murine AT-84 orthotopic model of oral cancer. Oral Dis 2003;9:305-12.
2. Lou E, Kellman RM, Shillitoe EJ. Effect of herpes simplex virus type-1 on growth of oral cancer in an immunocompetent, orthotopic mouse model. Oral Oncol 2002;38:349-56.
3. Ikeda K, Ichikawa T, Wakimoto H, et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med 1999;5:881-7.
4. Ikeda K, Wakimoto H, Ichikawa T, et al. Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication- conditional herpes simplex virus mutant. J Virol 2000;74:4765-75.
5. Miller C, Fraser NW. Role of the immune response during neuro-attenuated herpes simplex virus-mediated tumor destruction in a murine intracranial melanoma model. Cancer Res 2000;60:5714-22.
6. Toda M, Rabkin SD, Kojima H, Martuza RL. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther 1999;10:385-93.
7. Shillitoe EJ, Gilchrist E, Pellenz C, Murrah V. Effects of herpes simplex virus on human oral cancer cells, and potential use of mutant viruses in therapy of oral cancer. Oral Oncol 1999;35:326-32.
8. Carew JF, Kooby DA, Halterman MW, Federoff HJ, Fong Y. Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type-1 (G207). Hum Gene Ther 1999;10:1599-606.
9. Hukkanen V, Mikola H, Nykanen M, Syrjanen S. Herpes simplex virus type 1 infection has two separate modes of spread in three-dimensional keratinocyte culture. J Gen Virol 1999;80:2149-55.
10. Banks TA, Hariharan MJ, Rouse BT. Assessing cell-mediated immune responses to HSV in murine systems. In: Brown SM, MacLean AR, editors. Herpes simplex virus protocols. Totowa (NJ): Humana Press; 1998. p. 327-43.
11. Henry C. Hemolytic plaque assays. In: Mishell BB, Shiigi SM, Mishell RI, editors. Selected methods in cellular immunology San Francisco: WH Freeman and Company; 1980. p. 69-123.
12. Oda T, Maeda H. A new simple fluorometric assay for phagocytosis. J Immunol Meth 1986;88:175-83.
13. Tanigawa M, Bigger JE, Kanter MY, Atherton SS. Natural killer cells prevent direct anterior-to-posterior spread of herpes simplex virus type-1 in the eye. Invest Ophthalmol Vis Sci 2000;41:132-7.
14. Klerx J, Beukelman C, Van Dijk H, Willers J. Microassay for colorimetric estimation of complement activity in guinea pig, human and mouse serum. J Immunol Methods 1983;63:215-20.
15. Clayman GL, Trapnell BC, Mittereder N, et al. Transduction of normal and malignant oral epithelium by an adenovirus vector: the effect of dose and treatment time on transduction efficiency and tissue penetration. Cancer Gene Ther 1995;2:105-11.
16. Lapidot T, Fajerman Y, Kollet O. Immune-deficient SCID and NOD/SCID mice models as functional assays for studying normal and malignant human hematopoiesis. J Mol Med 1997;75:664-73.
17. Syrjanen S, Mikola H, Nykanen M, Hukkanen V. In vitro establishment of lytic and nonproductive infection by herpes simplex virus type-1 in three-dimensional keratinocyte culture. J Virol 1996;70:6524-8.
18. Visalli R, Courtney R, Meyers C. Infection and replication of herpes simplex virus type-1 in an organotypic epithelial culture system. Virology 1997;230:236-43.
19. Advani S, Weichselbaum R, Whitley R, Roizman B. Friendly fire: redirecting herpes simplex virus-1 for therapeutic applications. Clin Microbiol Infect 2002;8:551-63.
20. Schang L, Bantly A, Knockaert M, et al. Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral, proteins. J Virol 2002;76:7874-82.
21. Moffat J, McMichael M, Leisenfelder S, Taylor S. Viral and cellular kinases are potential antiviral targets and have a central role in varicella zoster virus pathogenesis. Biochim Biophys Acta 2004;1697:225-31.
22. Nimeus E, Baldetorp B, Bendahl P, et al. Amplification of the cyclin D1 gene is associated with tumour subsite, DNA non-diploidy and high S-phase fraction in squamous cell carcinoma of the head and neck. Oral Oncol 2004;40:624-9.
23. Michels JJ, Marnay J, Plancoulaine B, Chasle J. Flow cytometry in primary breast carcinomas: prognostic impact of S-phase fraction according to different analysis patterns. Cytometry B Clin Cytom 2004;59:32-9.